id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333140-cdikbi1l	Zhao, Helong	Imatinib is not a potent anti-SARS-CoV-2 drug	2020-09-30		.txt	text/plain	913	52	43	We tested the effects of imatinib and asciminib, a highly specific and potent ABL inhibitor binding to the myristate pocket of the kinase domain [7] , on SARS-CoV-2 infection and replication in the naturally susceptible ACE2 + human Caco-2 cells [5] . We then performed the standard viral replication assay using the USA-WA1/2020 strain of SARS-CoV-2 to test imatinib and asciminib in a blinded fashion, including remdesivir as a positive control. Therefore, our data indicate that, within clinically achievable dose ranges, imatinib and asciminib have no significant effect on SARS-CoV-2 infection and replication. These data support additional prospective investigations into the potential beneficial effect of imatinib and possibly other ABL inhibitors on COVID-19, but provide insufficient evidence for the off-label use of imatinib in patients with COVID-19. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. Imatinib is not a potent anti-SARS-CoV-2 drug	./cache/cord-333140-cdikbi1l.txt	./txt/cord-333140-cdikbi1l.txt